Comparative Pharmacology
Head-to-head clinical analysis: ALPHAZINE versus CHLORPROMAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAZINE versus CHLORPROMAZINE HYDROCHLORIDE.
ALPHAZINE vs CHLORPROMAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist in the central nervous system, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and heart rate.
Antagonizes dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histamine H1, muscarinic, and serotonin receptors.
Adults: IM/SC 10 mg every 4 hours as needed, maximum 40 mg/day; IV 5 mg over 1 minute, may repeat in 20-30 minutes, maximum 10 mg.
25-100 mg orally or intramuscularly every 4-6 hours; maximum 2 g/day orally or 1 g/day intramuscularly.
None Documented
None Documented
5-7 hours; prolonged to 10-15 hours in renal impairment.
Terminal elimination half-life 30 ± 14 hours (range 20–70 hours); clinical context: requires multiple daily dosing in acute agitation, but long-acting IM formulations (not chlorpromazine) available; half-life increases with age and hepatic impairment.
Primarily renal (60-70% unchanged), 20-30% biliary/fecal as metabolites.
Primarily hepatic metabolism; renal excretion accounts for ~20% as unchanged drug and metabolites, with ~6% unchanged; biliary/fecal excretion ~80%, mainly as metabolites.
Category C
Category C
Antipsychotic
Antipsychotic